The FDA plans to introduce a fast-track review process for diabetes drugs, which would make the market more attractive as products would spent less time in development and more time on the market under patent.
Impact of non-invasive insulins
The non-invasive insulins in development have the potential to revolutionise the insulin market. Currently many type 2 patients are put off using insulin because of its injection delivery and patient compliance amongst those who do use it is low. Thus an oral or inhaled insulin would tap into the lucrative type 2 market and encourage further use of insulin.
Race for the first dual PPAR agonist
These drugs have blockbuster potential in halting the progression of both diabetes and heart disease, thus sales of not only diabetes products but also cardiovascular products. However, concerns over safety of such drugs may delay their entry on the market.
Rising rates of obesity
Diabetes type 2 has now reached epidemic levels, affecting over 30 million people in the US and Europe, with this figure projected to rise to over 40 million by 2012. The rise in obesity rates and the increasing age demographic are key drivers of this epidemic.
Your questions answered
- Which sectors of the diabetes market are currently driving growth? - Why is insulin being increasingly prescribed for type 2 diabetic patients? - Which products in development will drive future growth? - Which products are at risk from genericization in the coming years? - How can the lifecycle of diabetes drugs be managed and extended? - Who are the key players in the insulin and OAD markets? - How are companies shaping themselves to become the diabetes leaders of tomorrow?
